Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has announced a 1-for-25 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and reduce the public float. The reverse split will reduce the number of outstanding shares from approximately 30.5 million to about 1.2 million. The move is intended to make the bid price more attractive to a broader group of investors and maintain the listing of its common stock on the Nasdaq Capital Market.